Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PEEL-224
- Development stage
- Phase 2
- Lead developer
- PEEL Therapeutics
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
PEEL-224 is a novel small molecule nanoparticle topoisomerase I inhibitor developed for the treatment of advanced and refractory solid tumors, including pediatric cancers. The active molecule in PEEL-224 is derived from camptothecin, a natural compound found in the leaves and stem of *Camptotheca acuminata* (the "Happy Tree"), which has been used in traditional Chinese medicine. Through chemical optimization and nanocarrier assembly, PEEL-224 aims to improve tumor delivery and reduce toxicity compared to conventional chemotherapy agents like irinotecan. Preclinical studies have shown that it can overcome chemoresistance, with promising activity even against drug-resistant tumors. It is currently being evaluated as monotherapy and in combination with vincristine and temozolomide for various solid tumors—including neuroblastoma, Ewing sarcoma, rhabdomyosarcoma, desmoplastic small round cell tumor (DSRCT), osteosarcoma, primitive neuroectodermal tumors (PNET), peripheral neuroectodermal tumors (PNET), small cell sarcoma—and other aggressive pediatric cancers[1][2][3][5][6][7][8].
- Other names
- PEEL-224PEEL224PEEL 224PEG-[SN22]4
02
Targets
TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on PEEL-224.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PEEL-224.